Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UNH5
UPID:
CC14A_HUMAN
Alternative names:
CDC14 cell division cycle 14 homolog A
Alternative UPACC:
Q9UNH5; A6MA65; B1AQ14; B1AQ15; O43171; O60727; O60728; Q52LH9; Q8IXX0
Background:
Dual specificity protein phosphatase CDC14A plays a pivotal role in cell division, specifically in centrosome separation and cytokinesis. It acts by dephosphorylating key proteins such as SIRT2 and possibly FZR1/CDH1, facilitating the exit from mitosis. Additionally, CDC14A is essential for normal hearing, highlighting its diverse biological functions.
Therapeutic significance:
CDC14A's involvement in non-syndromic sensorineural hearing loss, particularly DFNB32, which is characterized by prelingual, progressive, moderate to profound deafness, underscores its therapeutic potential. Understanding the role of CDC14A could open doors to potential therapeutic strategies for hearing loss and related conditions.